What drug is spelled ENSSNMIFSN (Ensifentrine) for the patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ensifentrine (brand: Ohtuvayre) — What drug is this?

Ensifentrine is a nebulized dual PDE3/4 inhibitor for COPD, branded as Ohtuvayre, that improves lung function, symptoms, and quality of life without proven mortality benefit. 1, 2, 3

  • What it is

    • Inhaled suspension (3 mg per unit-dose ampule) delivered via standard jet nebulizer; mechanism: dual PDE3 (bronchodilation) and PDE4 (anti-inflammatory) inhibition 1.
    • FDA-approved for COPD; not established in pediatrics 1.
    • Dosing/device specifics: use PARI-type jet nebulizer with mouthpiece; shake ampule vigorously before use 1.
  • Why it matters for morbidity and quality of life

    • Phase III data show improved FEV1, dyspnea, and COPD health status; signals for fewer exacerbations, supporting better QoL and reduced morbidity; no demonstrated mortality reduction to date 2, 3.
    • Meta-analysis (highest quality, recent): optimal efficacy at 3 mg, improvements in lung function and QoL without excess adverse events 3.
  • Safety and caveats

    • Common overdose signs: headache, tachycardia, palpitations; manage by holding drug and supportive care 1.
    • Hepatic impairment: exposure increases ~2.3-fold in moderate–severe; use with caution 1.
    • Renal impairment: no adjustment for mild–moderate; severe not studied 1.
    • Geriatric: similar safety/efficacy to younger adults; monitor sensitivity 1.
    • Admin pitfall: must use a compressor-driven jet nebulizer; avoid suboptimal devices that alter delivery 1.
  • How to position it clinically (to reduce exacerbation-related morbidity and improve QoL)

    • Consider in symptomatic moderate–severe COPD patients, including those on maintenance therapy, to improve lung function and symptoms and potentially reduce exacerbations (key driver of morbidity/QoL) 2, 3.
    • Do not rely on outdated COPD guidelines for this agent; those precede its approval and do not address ensifentrine 4, 5.
  • Notable nuance

    • Very preliminary data suggest potential hemodynamic and functional benefits in COPD-associated pulmonary hypertension, but evidence is weak (retrospective, n=5); do not use for PH management outside COPD optimization 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.